Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × elacestrant × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 21 Advanced Breast Cancer 2 Sarcoma, Endometrial Stromal 1 Recurrence 1 Perivascular Epithelioid Cell Neoplasms 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Endometrial Neoplasms 1 ER+ Breast Cancer 1 Central Nervous System Neoplasms 1 Central Nervous System Diseases 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Neoplasms, Male 1 Breast Diseases 1 Breast Cancer Patients 1 Brain Neoplasms 1 Brain Diseases 1 Adenosarcoma of the uterus 1

Interventions

pembrolizumab 102 Specimen Handling 52 Magnetic Resonance Spectroscopy 46 Nivolumab 45 Biopsy 45 Paclitaxel 34 Gemcitabine 32 Radiosurgery 28 Carboplatin 28 Ipilimumab 23 trastuzumab deruxtecan 22 Cyclophosphamide 22 Cisplatin 22 Irinotecan 21 Leucovorin 20 Capecitabine 20 Fluorouracil 19 Fulvestrant 18 Bevacizumab 18 Oxaliplatin 17 Drug Therapy 17 Cetuximab 17 130-nm albumin-bound paclitaxel 17 Taxes 16 Pemetrexed 16 Docetaxel 16 atezolizumab 15 Trastuzumab 15 olaparib 14 abemaciclib 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06201234 2025-12-01

ELEMENT

GBG Forschungs GmbH

Phase 2 Recruiting

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡